Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2014

Katsila Theodora, Juliachs Mercè, Gregori Josep, Macarulla Teresa, Villarreal Laura, Bardelli Alberto, Torrance Chris, Elez Elena, Tabernero Josep, Villanueva Josep

Abstract excerpt

PURPOSE: The lack of secreted biomarkers measurable by noninvasive tests hampers the development of effective targeted therapies against cancer. Our hypothesis is that cetuximab (an anti-EGFR mAb) induces a specific secretome in colorectal cancer cells that could be exploited for biomarker discovery. EXPERIMENTAL DESIGN: Considering the strong correlation between mutated KRAS and a lack of response to cetuximab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Proteome

Share to Proteomics

Share to ras Proteins

Share to Spheroids, Cellular

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 25324142
DOI: 10.1158/1078-0432.CCR-14-0361

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.PMID 25324142Read ↗

A catalogue of proteins released by colorectal cancer cells in vitro as an alternative source for biomarker discovery.Semantic proximity Read ↗

The secretome signature of colon cancer cell linesSemantic proximity Read ↗

Characterisation of Colorectal Cancer Cell Lines through Proteomic Profiling of Their Extracellular VesiclesSemantic proximity Read ↗

Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor lineSemantic proximity Read ↗

Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors.Semantic proximity Read ↗

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.Semantic proximity Read ↗

Immunoscreening of the extracellular proteome of colorectal cancer cellsSemantic proximity Read ↗

Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies.Semantic proximity Read ↗

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.Semantic proximity Read ↗

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.Semantic proximity Read ↗

Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceSemantic proximity Read ↗

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.